BioSpace News Archive

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will present the company’s corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) today announced that it has dosed the first patients in an ethnobridging study in healthy adult Japanese and non-Asian subjects to compare the safety and pharmacokinetic profiles of SLS-002 (intranasal racemic ketamine).

RNAimmune, Inc. announced today that its RNAimmune mRNA cancer vaccine program has been accepted for oral presentation at the AACR Annual Meeting 2023.

Scholar Rock today announced the appointment of Tracey M. Sacco as Chief Commercial Officer.

Rubedo Life Sciences announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company an $1.45M grant.

The Access to Advanced Health Institute (AAHI) announced today that it has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate based on AAHI’s self-amplifying RNA (saRNA) platform that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.

Alercell celebrates today World Cancer Day in unveiling its Poster for World Cancer Day. World Cancer Day was born on the 4 February 2000 at the World Summit Against Cancer for the New Millennium in Paris.

Crown Aesthetics, a division of Crown Laboratories, is excited to announce the launch of its new Premium Biocellulose Masque for post-treatment skin soothing.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the appointment of Barbara Duncan to its Board of Directors.